

FOR IMMEDIATE RELEASE
Balerna, 12th April 2007

SANOFI-AVENTIS launches in the Belgian Market an innovative balsamic decongestant cream for Cough & Cold developed by APR Applied Pharma Research SA.

“The APR decongestant cream is the product we were looking for” said Brigitte Leclercq, Product Manager of Sanofi-Aventis, “ the concept of a rub cream is good and well established, but it’s not enough, patients now require the products to be clean, safe, non greasy, enjoyable, well suited for both kid’s and adult use, and APR balsamic decongestant cream meet all these characteristics”.

Sanofi-Aventis, after signing an exclusive license agreement with APR for Belgium and Luxemburg, recently launched in the market the balsamic decongestant cream with the brand Rhina-care, in two versions, adults and kids.

“Cough & Cold is quite a mature market, but if you look at it in the correct way there is still room for innovation, says Paolo Galfetti, CEO of APR Applied Pharma Research SA. “Rub creams and products for inhalation are in the market since many years and most of these products are very old formulations that do not fit with the most advanced development standards in terms of pleasantness of use, cleanness and safety. We applied the most advanced criteria to obtain a decongestant cream, to be used both as rub-cream and as inhaler, to be nice to use, safe and clean and we are very proud that a company like Sanofi-Aventis recognized these points as key advantages in the market “.

The APR balsamic decongestant cream is a product fully developed by APR Applied Pharma Research SA in two versions, adult and baby (with and without menthol and camphor) and intended for use as a rub-cream, to be directly inhaled from the stick, or to be poured in warm water for vapours inhalation.

About APR Applied Pharma Research s.a.

APR Applied Pharma Research s.a. (APR) is a Swiss based, independent drug delivery and drug development company focusing its efforts in creating value on its own selected drug candidates which are licensed out to third parties for distribution and marketing as well as on third party products under contract research and development. APR uses its proprietary technologies and drug delivery systems, its development and regulatory know how as well as its licensing network to create value on innovative products and projects.

APR is structured to manage internally product/project research & development activities from formulation development to finished CTD registration dossier ready for submission in EU as one stop shop for any oral and topical project. For more information, please visit the APR web site at: www.apr.ch or contact Paolo Galfetti, CEO of APR at paolo.galfetti@apr.ch

About Sanofi-Aventis

Sanofi-Aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe and number three in Belgium. Backed by a world-class R&D organisation, Sanofi-Aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.

Sanofi-Aventis Belgium has an office in Diegem and a distribution center in Boortmeerbeek. The main activities are clinical development, registration, marketing, sales and distribution of prescription medicines and over-the-counter medicines. For more information, please visit the Sanofi-Aventis website at: www.sanofi-aventis.be